Breaking news on Acid Reflux and GORD
Anti-Hypertensive Drugs To Enhance Esophageal Contraction published
Mon, 08 Mar 2010 02:00:00 PST
Nifedipine, a calcium-channel blocker, was shown to decrease lower esophageal sphincter pressure and increase esophageal acid exposure time, while atenolol, a b1 blocker, was shown to inhibit relaxation of the smooth muscle of the esophagus...
New Endoscopic Treatment May Spare Barrett's Esophagus Patients From Surgery published
Sat, 20 Feb 2010 00:00:00 PST
Early tumor formation in Barrett's esophagus (BE) can be effectively and safely treated with radiofrequency ablation (RFA), in combination with prior endoscopic removal of visible lesions, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute...
Shape Of Barrett's Epithelium Effects Prevalence Of Erosive Esophagitis published
Mon, 08 Feb 2010 01:00:00 PST
Barrett's epithelium is recognized as a complication of erosive esophagitis and is the pre-malignant condition for adenocarcinoma of the esophagus. A research team from Yokohama City University School of Medicine hypothesized that some macroscopic features of Barrett's epithelium might be useful for identifying a subgroup with a high risk for the development of esophageal adenocarcinoma...
New Hope For Therapy In Heartburn-Related Cancer published
Wed, 13 Jan 2010 00:00:00 PST
Cancer of the gullet, or oesophagus, is one of the ten most common cancers in the Western world, and there have been recent alarming increases in the number of cases each year in the US and UK. There is no good treatment, and sufferers frequently face a short, painful battle which ends all too quickly in death. Many of the cancers diagnosed are in people with a long history of heartburn...
Development Of ADX10059 Ended For Long-Term Use published
Wed, 23 Dec 2009 00:00:00 PST
Addex Pharmaceuticals (SWISS: ADXN) announced that based on preliminary review of the unblinded data from study 206, it has terminated development of ADX10059 for chronic indications, including long term treatment of gastroesophageal reflux disease and migraine prophylaxis...
Amneal Receives FDA Approval For Nizatidine Oral Solution, The First Generic Oral Solution For Axid(R) In The Market published
Thu, 10 Dec 2009 16:00:00 PST
Amneal Pharmaceuticals is pleased to announce that it has received U.S. FDA approval to manufacture Nizatidine Oral Solution in the 15 mg/mL strength effective November 18, 2009. It is an AA-rated, therapeutically equivalent alternative to Axid® Oral Solution (a licensed trademark of Braintree Labs)...
Are Manometric Findings Different Between Patients With Erosive And Nonerosive Disease? published
Wed, 09 Dec 2009 05:00:00 PST
Gastroesophageal reflux disease (GERD) is defined as the pathological retrograde movement of gastric contents into the esophagus. Various esophageal motility disturbances which may be important in reflux are observed in patients with GERD. The main esophageal motility disorder in these patients is ineffective esophageal motility (IEM)...
Why Does Percutaneous Endoscopic Gastrostomy Fail To Eliminate Gastroesophageal Reflux? published
Wed, 09 Dec 2009 05:00:00 PST
Gastroesophageal reflux (GER) is a common problem in mechanically ventilated patients and contributes to the development of esophageal mucosal injury and even erosive esophagitis. The relationship between percutaneous endoscopic gastrostomy (PEG) and subsequent development of GER is complex and not well understood...
Strengthening Sphincters In Animals Via Muscle Cell Infusion published
Mon, 07 Dec 2009 00:00:00 PST
A new study shows that muscle cells grown in the lab can restore an intestine's ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat patients with conditions such as gastric reflux and fecal incontinence. This technique may be used to strengthen sphincters, which are the bands of muscle that separate the major sections of your intestinal tract...
FDA Approves ZEGERID OTC(TM) For Over-the-Counter Treatment Of Frequent Heartburn published
Wed, 02 Dec 2009 01:00:00 PST
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ZEGERID OTC(TM) (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), for over-the-counter treatment of frequent heartburn. ZEGERID OTC will be marketed over-the-counter by Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc...
News From The November Issue Of GIE: Gastrointestinal Endoscopy published
Wed, 25 Nov 2009 01:00:00 PST
"Screening for Barrett's esophagus in asymptomatic women" Barrett's esophagus is a condition where the lining of the esophagus changes due to chronic inflammation, generally from gastroesophageal reflux disease (GERD). Barrett's esophagus is important to recognize as it may increase the risk of developing esophageal cancer...
Reflux Esophagitis Due To Immune Reaction, Not Acute Acid Burn published
Fri, 20 Nov 2009 01:00:00 PST
Contrary to current thinking, a condition called gastroesophageal reflux disease (GERD) might not develop as a direct result of acidic digestive juices burning the esophagus, UT Southwestern Medical Center researchers have found in an animal study. Rather, gastroesophageal reflux spurs the esophageal cells to release chemicals called cytokines, which attract inflammatory cells to the esophagus...
Addex ADX10059 Monotherapy Is Effective On GERD Symptoms In Phase IIb Clinical Trial published
Mon, 16 Nov 2009 03:00:00 PST
Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced that it achieved statistically significant efficacy on the primary endpoint, increasing the number of symptom free days in the Phase IIb trial of ADX10059 as a monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms...
Mylan Receives FDA Approval For Generic Version Of Prevacid® Through Its Subsidiary Matrix Laboratories published
Thu, 12 Nov 2009 02:00:00 PST
Mylan Inc. (NASDAQ: MYL) announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) Capsules, 15 mg and 30 mg. This product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand...
Open Wide: Incisionless Surgery To Treat GERD published
Wed, 11 Nov 2009 02:00:00 PST
Every day, more than 20 percent of the U.S. population experiences the painful burning symptoms of gastroesophageal reflux disease (GERD). For these 20 million Americans, the first line of defense is medication...
FDA Approves New Salix Product Exclusively In Catalent's Zydis(R) Fast Dissolve Technology published
Wed, 04 Nov 2009 18:00:00 PST
Catalent Pharma Solutions, one of the leading advanced drug delivery technology providers to the pharmaceutical industry, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Metozolv™ ODT (orally disintegrating tablets) metoclopramide HCL utilizing Catalent's Zydis® fast dissolve technology...
Unexpected Consequences Of Proton Pump Inhibitor Use In Reflux Disease published
Mon, 02 Nov 2009 03:00:00 PST
Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Physicians are warned to monitor these effects and prescribe these medications carefully, according to a new commentary published in the November 2009 issue of Otolaryngology -Head and Neck Surgery...
New Procedure For Acid Reflux/GERD published
Tue, 27 Oct 2009 05:00:00 PST
Boston Medical Center (BMC) surgeons are now offering patients an incisionless alternative to laparoscopic and traditional surgery for treatment of acid reflux or GERD. Using the new procedure known as EsophyX TIF (Transoral Incisionless Fundaplication), surgeons can repair or reconstruct the valve between the esophagus and stomach, effectively stopping GERD...
New Studies Explore Connection Between High Stress And High Exposure Jobs And GI Disorders published
Tue, 27 Oct 2009 01:00:00 PST
In two new studies, presented at the American College of Gastroenterology's (ACG) 74th Annual Scientific meeting in San Diego, researchers explored the connection between high stress, high exposure occupations and long-term gastrointestinal disorders...
New Study Results Analyzed The Use Of KAPIDEX(TM) (dexlansoprazole) For Nighttime Heartburn In Adults With Non-Erosive GERD published
Tue, 27 Oct 2009 01:00:00 PST
New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD),...
Possible Weight-Gain From Long-Term Treatment With Proton Pump Inhibitor published
Mon, 26 Oct 2009 01:00:00 PST
Gastroesophageal reflux disease (GERD) is the most common esophageal disorder, and frequently encountered in the primary care setting. Accumulating evidence has confirmed the excellent efficacy and safety of proton pump inhibitor (PPI) therapy in patients with all grades of GERD, making these agents the mainstay of treatment...
XenoPort Announces Initiation Of A Phase 2b Clinical Trial Of Arbaclofen Placarbil In Patients With Gastroesophageal Reflux Disease published
Wed, 21 Oct 2009 01:00:00 PST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI)...
Heartburn Drugs Deemed Safe For Fetuses According To Ben-Gurion University Researchers published
Fri, 09 Oct 2009 00:00:00 PST
H2 Blocker drugs, such as Famotidine, Cimetidine and Ranitidine, approved in the U.S. for acid reflux (heartburn), pose no significant risks for the fetus according to a large collaborative cohort study by researchers at Ben-Gurion University of the Negev...
Addex Completes Enrollment Of First Mid-Stage Clinical GERD Trial published
Mon, 28 Sep 2009 02:00:00 PST
Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the completion of enrollment in the Phase IIb trial of ADX10059 as a monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms...
Mayo Clinic Researchers Lead National Clinical Trial Testing New Treatment For Chronic, Severe Indigestion published
Fri, 18 Sep 2009 01:00:00 PST
Could medicines used for depression also treat chronic, severe indigestion? Scientists at Mayo Clinic suspect they can and, backed by funding from the National Institutes of Health (NIH), they are testing that premise in a nationwide clinical trial...
|
|
